A. Calvert

发表

Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer

M. Millward, D. Newell, K. Yuen, 2004, Cancer Chemotherapy and Pharmacology.

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

M. Noble, J. Endicott, N. Curtin, 2003, Bioorganic & medicinal chemistry letters.

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

N. Curtin, B. Durkacz, D. Newell, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials

R. Plummer, A. Calvert, A. H. Calvert, 2008, Clinical Cancer Research.

Some observations on the human pharmacology of methotrexate.

A. Calvert, K. Harrap, A. H. Calvert, 1977, Cancer treatment reports.

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

N. Curtin, D. Newell, A. Calvert, 2001, British Journal of Cancer.

2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.

Roger N Gunn, A. Boddy, S. Osman, 2003, Journal of the National Cancer Institute.

Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.

A. Boddy, D. Newell, A. Calvert, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.

N. Curtin, P. Smith, D. Newell, 1999, Seminars in oncology.

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).

G. Giaccone, E. Eisenhauer, L. Seymour, 2008, European journal of cancer.

The intracellular mechanism of action of metoprine (DDMP).

G. Browman, A. Calvert, K. Harrap, 1980, European journal of cancer.

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations

A. Boddy, A. Maraveyas, A. Calvert, 2005, British Journal of Cancer.

Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.

A. Calvert, M. Egorin, A. H. Calvert, 2002, European journal of cancer.

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.

M. Piccart, R. Paridaens, P. Therasse, 2003, European journal of cancer.

Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours

A. Boddy, N. Bleehen, M. Lind, 2000, Cancer Chemotherapy and Pharmacology.

Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies

G. Giaccone, E. Eisenhauer, A. Calvert, 2012 .

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas

R. Plummer, R. Salazar, A. Calvert, 2011, Investigational New Drugs.

Fishing for new drugs.

A. Calvert, A. H. Calvert, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.

G. Rustin, N. Bleehen, E. Newlands, 1998, British Journal of Cancer.

The use of pharmacokinetics to improve the treatment of ovarian cancer: combination paclitaxel (Taxol®)–carboplatin

A. Calvert, A. H. Calvert, 1997 .

Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly ( ADP-ribose ) Polymerase

N. Curtin, R. Griffin, B. Golding, 2022 .

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

A. Boddy, D. Newell, A. Calvert, 2002, European journal of cancer.

Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.

M. Stevens, C. R. Pinkerton, I. Lewis, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid

A. Boddy, S. Wedge, D. Newell, 2004, Investigational New Drugs.

Clinical studies with MTA.

A. Calvert, J. Walling, A. H. Calvert, 1998, British Journal of Cancer.

Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies

R. Plummer, J. Bono, A. Calvert, 2005 .

Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

N. Curtin, R. Griffin, B. Golding, 2003, Journal of medicinal chemistry.

Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

N. Curtin, L. Pemberton, R. Griffin, 1998, Journal of medicinal chemistry.

Biochemical pharmacology of pemetrexed.

A. Calvert, A. H. Calvert, 2004, Oncology.

Carboplatin/cisplatin

A. Harris, A. Horwich, M. Slevin, 2012, Reactions Weekly.

Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E

J. Wanders, E. Raymond, A. Calvert, 2000 .

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

D. Miles, I. Smith, A. Calvert, 2001, European journal of cancer.

Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

G. Giaccone, E. Eisenhauer, L. Seymour, 2013, European journal of cancer.

Advanced epithelial ovarian cancer: 1998 consensus statements.

J. Neijt, G. Rustin, J. Berek, 1993 .

Cisplatin/carboplatin cross-resistance in ovarian cancer.

M. Gore, A. Calvert, B. Robinson, 1989, British Journal of Cancer.

A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

D. Newell, A. Calvert, A. H. Calvert, 2009, Cancer Chemotherapy and Pharmacology.

JM8, SUCCESSOR TO CISPLATIN IN ADVANCED OVARIAN CARCINOMA?

A. Calvert, B. Evans, E. Wiltshaw, 1983, The Lancet.

Combining cisplatin and carboplatin complementary or contradictory?

A. Calvert, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed safety and dosing strategy.

P. Bunn, A. Calvert, P. Paoletti, 2002, Seminars in oncology.

The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.

M. Millward, M. Lind, F. Chapman, 1995, British Journal of Cancer.

A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.

P. Vasey, S. Kaye, A. Calvert, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

The pharmacokinetics of the quinazoline antifolate ICID 1694 in mice and rats

D. Newell, A. Calvert, D. Jodrell, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse.

P. O'Connor, D. Newell, A. Calvert, 1986, Cancer treatment reports.

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

N. Curtin, R. Griffin, B. Golding, 1995, Biochimie.

Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study

J. Sludden, A. Boddy, D. Bisset, 2001 .

A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors

M. Zucchetti, J. Carmichael, A. Calvert, 1999 .

The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of [3H]thymidine in the rat.

P. O'Connor, D. Newell, A. Calvert, 1986, Biochemical pharmacology.

Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP).

N. Curtin, J. K. Porteous, L. Pemberton, 1995, Anti-cancer drug design.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

N. Curtin, R. Griffin, B. Golding, 2004, Journal of medicinal chemistry.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Robert Almassy, Kaye J Williams, N. Curtin, 2004, Journal of the National Cancer Institute.

Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.

N. Curtin, R. Griffin, B. Golding, 2000, Journal of medicinal chemistry.

Novel Benzimidazole and Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP‐ribose)polymerase*

N. Curtin, R. Griffin, B. Golding, 1996 .

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

E Wiltshaw, A H Calvert, M. Gore, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.

N. Curtin, P. Smith, Peter G. Smith, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

N. Curtin, R. Griffin, Yan Zhao, 2006, Cancer research.

157 ESTIMATION OF THE IN VITRO AND IN VIVO INHIBITORY EFFECTS OF ANTIFOLATES UPON THYMIDYLATE SYNTHASE (TS) IN WHOLE CELLS

A. Calvert, K. Balmanno, A. Jackman, 1988, Pediatric Research.

Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.

N. Curtin, Peter G. Smith, R. Griffin, 2004, Journal of medicinal chemistry.

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

G. Peters, H. McLeod, E. Bloemena, 2002, Biochimica et biophysica acta.

Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines).

N. Curtin, R. Griffin, B. Golding, 1994, Anti-cancer drug design.

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer

D. Neal, J. Lunec, A. Calvert, 1996, Nature Medicine.

Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

D. Newell, A. Calvert, T. Mcelwain, 1983, British journal of clinical pharmacology.

The clinical pharmacology of chlorambucil and prednimustine.

D. Newell, A. Calvert, T. Mcelwain, 1983, British journal of clinical pharmacology.

Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer.

C. Robson, A. Calvert, V. Gnanapragasam, 2008, Human pathology.

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

A. Boddy, A. Calvert, H. Thomas, 1997, British Journal of Cancer.

Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.

G. Giaccone, J. Doroshow, A. Calvert, 2009, European Journal of Cancer.

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

M. Highley, A. Boddy, M. Cole, 2002, British journal of clinical pharmacology.

Phase 1/2 study of oral rucaparib: Final phase 1 results.

G. Shapiro, P. LoRusso, H. Burris, 2014 .

JM8 (CISPLATIN ANALOGUE) ALONE FOR PREVIOUSLY UNTREATED ADVANCED OVARIAN CARCINOMA

J. Neijt, A. Calvert, B. Evans, 1983, The Lancet.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

N. Curtin, B. Durkacz, D. Newell, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

M. Tilby, D. Newell, A. Calvert, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

S. Baker, A. Calvert, P. Paoletti, 2002, Molecular cancer therapeutics.

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

G. Jayson, T. Ganesan, P. Vasey, 2004, Gynecologic oncology.

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

I. Smith, A. Calvert, S. Harland, 2004, Cancer Chemotherapy and Pharmacology.

Editorial: Combining cisplatin and carboplatin complementary or contradictory?

A. Calvert, 1991 .

Studies on the Mechanism of CB 3717 Induced Hepatotoxicity

A. Calvert, K. Harrap, N. Dr, 1984 .

High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.

M. Gore, A. Calvert, A. H. Calvert, 1987, European journal of cancer & clinical oncology.

The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)

D. Newell, A. Calvert, S. Harland, 2004, Cancer Chemotherapy and Pharmacology.

Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors

J. Sludden, A. Boddy, D. Bissett, 2003 .

ALIMTATM in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial

M. Highley, R. Plummer, A. Calvert, 2000 .

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

N. Curtin, R. Griffin, B. Golding, 2002, Journal of medicinal chemistry.

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).

G. Giaccone, E. Eisenhauer, L. Seymour, 2008, European journal of cancer.

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

J. Sludden, A. Boddy, D. Bissett, 2005, Clinical Cancer Research.

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

A H Calvert, E. Sausville, L. Johnson, 2000, Journal of medicinal chemistry.

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

N. Bleehen, G. Rustin, N. Bleehen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

I. Judson, D. Talbot, I. Smith, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.

D. Newell, A. Calvert, M. Graham, 1989, Journal of chromatography.

Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.

M. Gore, I. Smith, Z. Siddik, 1987, European journal of cancer & clinical oncology.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

M. Piccart, L. Duchateau, C. Lohrisch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Adrian L Harris, A. Harris, A. Boddy, 2005, Clinical Cancer Research.

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Christopher Poole, Tien Le, Susan Ellard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclin dependent kinase inhibitors

L. Meijer, M. Noble, J. Endicott, 2003 .

A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI

Suzanne F. Jones, H. Wakelee, B. Sikic, 2007 .

Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.

R. Griffin, B. Golding, A. Calvert, 2011, Journal of medicinal chemistry.

Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.

D. Newell, A. Calvert, A. Jackman, 1988, Biochemical pharmacology.

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

A. Schätzlein, J. Sludden, A. Boddy, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity 1 , 2

N. Curtin, Peter G. Smith, R. Griffin, 2001 .

A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder

P. Wilkinson, L. Freedman, D. Newling, 1987 .

First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors

R. Plummer, A. Calvert, M. Middleton, 2005 .

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations

A. Calvert, C. Kelly, A. Azzabi, 2005, British Journal of Cancer.

JMS, successor to cisplatin in advanced ovarian carcinoma?

A. Calvert, A. Jones, E. Wiltshaw, 1983, Lancet.

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

G. Rustin, A. Calvert, N. Thatcher, 2002, Melanoma research.